CytomX Therapeutics Receives $70,000,000 Series D Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4a5fea5b-10d5-45b9-bb48-9c07aee1f37f - Date
6/17/2015 - Company Name
CytomX Therapeutics - Mailing Address
343 Oyster Point Blvd. South San Francisco, CA 94080 USA - Company Description
CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodies, proteolytically-activated antibodies. - Website
http://www.cytomx.com - Transaction Type
Venture Equity - Transaction Amount
$70,000,000 - Transaction Round
Series D - Proceeds Purposes
Proceeds from the financing will support the continued advancement of CytomX’s pipeline of Probody therapeutics toward clinical studies, including a Precision cancer immunotherapy directed against PD-L1 and Probody drug conjugates against novel, first in class targets. The financing will also support the expansion of Probody research and development activities in the areas of T-cell agonists, bispecific antibodies and engineered T-cell therapies. - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
